Abstract
BackgroundDespite immune checkpoint inhibitor (ICI) monotherapy approvals in NSCLC, SOC predominately utilizes combinations of ICI with non-targeted chemotherapy or precision therapies targeting oncogenic drivers. Biomarkers guiding these clinical decisions rely...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have